ATE407948T1 - Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität - Google Patents

Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität

Info

Publication number
ATE407948T1
ATE407948T1 AT98947759T AT98947759T ATE407948T1 AT E407948 T1 ATE407948 T1 AT E407948T1 AT 98947759 T AT98947759 T AT 98947759T AT 98947759 T AT98947759 T AT 98947759T AT E407948 T1 ATE407948 T1 AT E407948T1
Authority
AT
Austria
Prior art keywords
methods
compositions
specific cytotoxicity
inducing tumor
sequences
Prior art date
Application number
AT98947759T
Other languages
English (en)
Inventor
Abraham Hochberg
Suhail Ayesh
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE407948T1 publication Critical patent/ATE407948T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT98947759T 1997-10-03 1998-10-04 Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität ATE407948T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94360897A 1997-10-03 1997-10-03

Publications (1)

Publication Number Publication Date
ATE407948T1 true ATE407948T1 (de) 2008-09-15

Family

ID=25479934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98947759T ATE407948T1 (de) 1997-10-03 1998-10-04 Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität

Country Status (17)

Country Link
US (2) US6087164A (de)
EP (1) EP1019499B1 (de)
JP (3) JP5153031B2 (de)
KR (1) KR100524262B1 (de)
CN (1) CN1229496C (de)
AT (1) ATE407948T1 (de)
AU (1) AU755774B2 (de)
BR (1) BR9812717B1 (de)
CA (1) CA2308124C (de)
CZ (2) CZ294941B6 (de)
DE (1) DE69840001D1 (de)
HU (1) HU228470B1 (de)
IL (1) IL135430A0 (de)
NO (2) NO328470B1 (de)
PL (1) PL339949A1 (de)
RU (1) RU2214280C2 (de)
WO (1) WO1999018195A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1353935A4 (de) * 2000-12-07 2005-02-23 Penn State Res Found Selektionierung auf infektiöse agentien gerichteter katalytischer nukleinsäuren
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
JPWO2003102186A1 (ja) * 2002-05-31 2005-09-29 株式会社メディネット 癌細胞特異的発現誘導ｄｎａ、および癌細胞特異的発現ベクター
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7063947B2 (en) * 2004-04-08 2006-06-20 Promogen, Inc. System for producing synthetic promoters
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
WO2007007317A1 (en) 2005-07-07 2007-01-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
JP2009508516A (ja) 2005-09-22 2009-03-05 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法
CA2675967A1 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Nucleic acid constructs and methods for specific silencing of h19
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
BRPI0818937B8 (pt) 2007-10-25 2021-05-25 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd constructos contendo múltiplos cassetes de expressão para terapia de câncer
NZ590122A (en) * 2008-07-02 2012-02-24 Otsuka Pharma Co Ltd Artificial kidney precursor comprising a non-human mammalian metanephros and process for the production thereof
JP2012515532A (ja) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ， リミテッド Ｍｉｒ−２１プロモーター駆動性標的がん治療
EA016223B1 (ru) * 2009-10-07 2012-03-30 Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток
JP2018515479A (ja) * 2015-05-05 2018-06-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法
JP7749322B2 (ja) * 2018-04-30 2025-10-06 アミカス セラピューティックス インコーポレイテッド 遺伝子治療構築物及び使用方法
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN111206093A (zh) * 2018-11-21 2020-05-29 立森印迹诊断技术（无锡）有限公司 一种用于检测浸润性膀胱癌的标志物及其应用
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576303B1 (fr) * 1985-01-21 1987-04-10 Derivan Sa Procede d'obtention de squalene et de squalane a partir de sous-produits du raffinage des huiles vegetales
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique

Also Published As

Publication number Publication date
NO20001684D0 (no) 2000-03-31
EP1019499B1 (de) 2008-09-10
AU755774B2 (en) 2002-12-19
DE69840001D1 (de) 2008-10-23
KR100524262B1 (ko) 2005-10-28
IL135430A0 (en) 2001-05-20
WO1999018195A3 (en) 1999-08-12
US6306833B1 (en) 2001-10-23
JP5153031B2 (ja) 2013-02-27
AU9457198A (en) 1999-04-27
JP2001519148A (ja) 2001-10-23
NO20093194L (no) 2000-06-02
EP1019499A2 (de) 2000-07-19
PL339949A1 (en) 2001-01-15
NO328470B1 (no) 2010-02-22
BR9812717B1 (pt) 2011-06-28
CZ20001201A3 (cs) 2000-09-13
CA2308124A1 (en) 1999-04-15
CN1280616A (zh) 2001-01-17
HU228470B1 (en) 2013-03-28
CZ294941B6 (cs) 2005-04-13
JP2008136480A (ja) 2008-06-19
BR9812717A (pt) 2000-08-22
NO20001684L (no) 2000-06-02
CZ294694B6 (cs) 2005-02-16
US6087164A (en) 2000-07-11
HUP0003745A2 (hu) 2001-02-28
WO1999018195A2 (en) 1999-04-15
CA2308124C (en) 2008-07-08
RU2214280C2 (ru) 2003-10-20
CN1229496C (zh) 2005-11-30
JP2006304801A (ja) 2006-11-09
HUP0003745A3 (en) 2002-04-29
NO331723B1 (no) 2012-03-05
KR20010030912A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
DE69840001D1 (de) Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
IL135776A0 (en) Recombinational cloning using nucleic acids having recombination sites
AR110594A2 (es) Construcciones de expresión en plantas y método para expresar una secuencia de adn en plantas
PT1117672E (pt) Modulação anti-sentido da expressão de survivina
ATE129746T1 (de) Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
WO1999064579A3 (en) Corn oleosin promoter and genes encoding corn desaturases
DE69736432D1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
HRP950337B1 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
NO972373L (no) Vektorer for vevs-spesifikk replikasjon
BR9407956A (pt) Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
DE69535704D1 (de) EXPRESSIONSPLASMIDE, DURCH EINEN osmB PROMOTER REGULIERT
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ZA202300378B (en) Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
IL106894A0 (en) Dorsal tissue affecting factor and compositions
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU2164197A (en) Recombinant adenoviral vectors for human tumour gene therapy
ZA200202413B (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
ATE317020T1 (de) Neues regulationssystem zur kontrolle der expression eines transgens
WO2000078939A3 (de) Vektoren zur gentherapeutischen tumorbehandlung
DE59310334D1 (de) Vektor zur expression von therapeutisch relevanten genen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties